Loading…
Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis
OBJECTIVE: To evaluate the independent contribution of several clinical and laboratory variables to the mortality of a cohort of Danish patients with systemic sclerosis (SSc). METHODS: A cohort of 174 patients with incident SSc was retrospectively identified using clinical charts and study records o...
Saved in:
| Published in: | Journal of rheumatology 2001-11, Vol.28 (11), p.2454-2459 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 2459 |
| container_issue | 11 |
| container_start_page | 2454 |
| container_title | Journal of rheumatology |
| container_volume | 28 |
| creator | Jacobsen, S Ullman, S Shen, G Q Wiik, A Halberg, P |
| description | OBJECTIVE: To evaluate the independent contribution of several clinical and laboratory variables to the mortality of a cohort
of Danish patients with systemic sclerosis (SSc). METHODS: A cohort of 174 patients with incident SSc was retrospectively
identified using clinical charts and study records of all new patients with SSc. Disease onset was defined as the time of
onset of cutaneous sclerosis. Vital status and causes of death were determined at the end of the observation period. Data
on clinical status and pulmonary function were obtained. Antitopoisomerase I (anti-topo I), anticentromere, anti-U1-RNP, anti-U3-RNP,
anti-Th-RNP, and anti-RNA polymerase (anti-RNAP) antibodies were determined by means of double immunodiffusion, immunofluorescence,
hemagglutination technique, radioactively labelled antisense riboprobes, and ELISA, respectively. RESULTS: Patients were followed
for a mean period of 13.3 yrs; 16 died of an SSc related condition and 50 of other causes. Pulmonary fibrosis, DLCO reduction
< 40% of the expected, diffuse cutaneous involvement, SSc nephropathy, cardiac disease, and anti-topo I and anti-RNAP antibody
were related to decreased survival due to SSc. Variables that entered a Cox regression model of SSc related mortality were
right heart failure (RR 12.4, 95% CI 2.5-60), diffuse SSc (RR 7.8, 95% CI 1.8-35), SSc nephropathy (RR 6.1, 95% CI 1.8-21),
and DLCO < 40% (RR 4.8, 95% CI 1.1-20). The relative risk of developing right heart failure and diffuse SSc given the presence
of anti-RNAP antibody was 14 (p = 0.0001) and 1.9 (p = 0.01), respectively. The corresponding figures for anti-topo I antibody
were 4.6 (p = 0.02) and 2.0 (p = 0.01). CONCLUSION: SSc related mortality was associated with right heart failure and diffuse
SSc, both of which were also associated with the presence of anti-topo I and anti-RNAP antibody. The prognostic value of these
autoantibodies may lie in the early course of the disease when specific morbidity has not yet evolved. |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72271934</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72271934</sourcerecordid><originalsourceid>FETCH-LOGICAL-h269t-317c3d9a2817f77eeff122a0fb1c88c68ceebffebad832334b02715a63f24b183</originalsourceid><addsrcrecordid>eNpF0EtLxDAQwPEiiq6PryC5qBcLzWPb9CjiCwQvCt5Kmk7cSJqumcTiya9u1BVhIAP58T_MVrGgom1L1izZdrGoOF2WtGbPe8U-4mtV0VrUcrfYo7SppKByUXzeeeMSeA1kMkQ7661WjhhQMQXAc4IQ0kiUj9Yn7UCFn72fBvv9q_xAXPIvxCSvo508yYMpvNv3XMnFtYoWfEQy27gi-IERRqsJ5lSY0OJhsWOUQzjavAfF0_XV4-Vtef9wc3d5cV-uWN3GktNG86FVTNLGNA2AMZQxVZmeail1LTVAbwz0apCccS76ijV0qWpumOip5AfF6W93Haa3BBi70aIG55SHKWHXsOxbLjI83sDUjzB062BHFT66v5NlcLIBCvOpTFBeW_x3glLOa5bd2a9b2ZfVbAN0OCrncpZ38zwzmZMdE0vBvwAKPIZ4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72271934</pqid></control><display><type>article</type><title>Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis</title><source>Medical Journals</source><creator>Jacobsen, S ; Ullman, S ; Shen, G Q ; Wiik, A ; Halberg, P</creator><creatorcontrib>Jacobsen, S ; Ullman, S ; Shen, G Q ; Wiik, A ; Halberg, P</creatorcontrib><description>OBJECTIVE: To evaluate the independent contribution of several clinical and laboratory variables to the mortality of a cohort
of Danish patients with systemic sclerosis (SSc). METHODS: A cohort of 174 patients with incident SSc was retrospectively
identified using clinical charts and study records of all new patients with SSc. Disease onset was defined as the time of
onset of cutaneous sclerosis. Vital status and causes of death were determined at the end of the observation period. Data
on clinical status and pulmonary function were obtained. Antitopoisomerase I (anti-topo I), anticentromere, anti-U1-RNP, anti-U3-RNP,
anti-Th-RNP, and anti-RNA polymerase (anti-RNAP) antibodies were determined by means of double immunodiffusion, immunofluorescence,
hemagglutination technique, radioactively labelled antisense riboprobes, and ELISA, respectively. RESULTS: Patients were followed
for a mean period of 13.3 yrs; 16 died of an SSc related condition and 50 of other causes. Pulmonary fibrosis, DLCO reduction
< 40% of the expected, diffuse cutaneous involvement, SSc nephropathy, cardiac disease, and anti-topo I and anti-RNAP antibody
were related to decreased survival due to SSc. Variables that entered a Cox regression model of SSc related mortality were
right heart failure (RR 12.4, 95% CI 2.5-60), diffuse SSc (RR 7.8, 95% CI 1.8-35), SSc nephropathy (RR 6.1, 95% CI 1.8-21),
and DLCO < 40% (RR 4.8, 95% CI 1.1-20). The relative risk of developing right heart failure and diffuse SSc given the presence
of anti-RNAP antibody was 14 (p = 0.0001) and 1.9 (p = 0.01), respectively. The corresponding figures for anti-topo I antibody
were 4.6 (p = 0.02) and 2.0 (p = 0.01). CONCLUSION: SSc related mortality was associated with right heart failure and diffuse
SSc, both of which were also associated with the presence of anti-topo I and anti-RNAP antibody. The prognostic value of these
autoantibodies may lie in the early course of the disease when specific morbidity has not yet evolved.</description><identifier>ISSN: 0315-162X</identifier><identifier>EISSN: 1499-2752</identifier><identifier>PMID: 11708418</identifier><identifier>CODEN: JRHUA9</identifier><language>eng</language><publisher>Toronto, ON: The Journal of Rheumatology</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Antinuclear - blood ; Biological and medical sciences ; Cause of Death ; Child ; Cohort Studies ; Female ; Heart Diseases - etiology ; Heart Diseases - mortality ; Heart Diseases - pathology ; Humans ; Kidney Diseases - etiology ; Kidney Diseases - mortality ; Kidney Diseases - pathology ; Lung - pathology ; Lung - physiopathology ; Male ; Medical sciences ; Middle Aged ; Prognosis ; Prospective Studies ; Pulmonary Fibrosis - etiology ; Pulmonary Fibrosis - mortality ; Pulmonary Fibrosis - pathology ; Respiratory Function Tests ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Scleroderma, Systemic - complications ; Scleroderma, Systemic - mortality ; Scleroderma, Systemic - pathology ; Survival Analysis ; Survival Rate</subject><ispartof>Journal of rheumatology, 2001-11, Vol.28 (11), p.2454-2459</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14113362$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11708418$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jacobsen, S</creatorcontrib><creatorcontrib>Ullman, S</creatorcontrib><creatorcontrib>Shen, G Q</creatorcontrib><creatorcontrib>Wiik, A</creatorcontrib><creatorcontrib>Halberg, P</creatorcontrib><title>Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis</title><title>Journal of rheumatology</title><addtitle>J Rheumatol</addtitle><description>OBJECTIVE: To evaluate the independent contribution of several clinical and laboratory variables to the mortality of a cohort
of Danish patients with systemic sclerosis (SSc). METHODS: A cohort of 174 patients with incident SSc was retrospectively
identified using clinical charts and study records of all new patients with SSc. Disease onset was defined as the time of
onset of cutaneous sclerosis. Vital status and causes of death were determined at the end of the observation period. Data
on clinical status and pulmonary function were obtained. Antitopoisomerase I (anti-topo I), anticentromere, anti-U1-RNP, anti-U3-RNP,
anti-Th-RNP, and anti-RNA polymerase (anti-RNAP) antibodies were determined by means of double immunodiffusion, immunofluorescence,
hemagglutination technique, radioactively labelled antisense riboprobes, and ELISA, respectively. RESULTS: Patients were followed
for a mean period of 13.3 yrs; 16 died of an SSc related condition and 50 of other causes. Pulmonary fibrosis, DLCO reduction
< 40% of the expected, diffuse cutaneous involvement, SSc nephropathy, cardiac disease, and anti-topo I and anti-RNAP antibody
were related to decreased survival due to SSc. Variables that entered a Cox regression model of SSc related mortality were
right heart failure (RR 12.4, 95% CI 2.5-60), diffuse SSc (RR 7.8, 95% CI 1.8-35), SSc nephropathy (RR 6.1, 95% CI 1.8-21),
and DLCO < 40% (RR 4.8, 95% CI 1.1-20). The relative risk of developing right heart failure and diffuse SSc given the presence
of anti-RNAP antibody was 14 (p = 0.0001) and 1.9 (p = 0.01), respectively. The corresponding figures for anti-topo I antibody
were 4.6 (p = 0.02) and 2.0 (p = 0.01). CONCLUSION: SSc related mortality was associated with right heart failure and diffuse
SSc, both of which were also associated with the presence of anti-topo I and anti-RNAP antibody. The prognostic value of these
autoantibodies may lie in the early course of the disease when specific morbidity has not yet evolved.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Antinuclear - blood</subject><subject>Biological and medical sciences</subject><subject>Cause of Death</subject><subject>Child</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Heart Diseases - etiology</subject><subject>Heart Diseases - mortality</subject><subject>Heart Diseases - pathology</subject><subject>Humans</subject><subject>Kidney Diseases - etiology</subject><subject>Kidney Diseases - mortality</subject><subject>Kidney Diseases - pathology</subject><subject>Lung - pathology</subject><subject>Lung - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Pulmonary Fibrosis - etiology</subject><subject>Pulmonary Fibrosis - mortality</subject><subject>Pulmonary Fibrosis - pathology</subject><subject>Respiratory Function Tests</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Scleroderma, Systemic - complications</subject><subject>Scleroderma, Systemic - mortality</subject><subject>Scleroderma, Systemic - pathology</subject><subject>Survival Analysis</subject><subject>Survival Rate</subject><issn>0315-162X</issn><issn>1499-2752</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNpF0EtLxDAQwPEiiq6PryC5qBcLzWPb9CjiCwQvCt5Kmk7cSJqumcTiya9u1BVhIAP58T_MVrGgom1L1izZdrGoOF2WtGbPe8U-4mtV0VrUcrfYo7SppKByUXzeeeMSeA1kMkQ7661WjhhQMQXAc4IQ0kiUj9Yn7UCFn72fBvv9q_xAXPIvxCSvo508yYMpvNv3XMnFtYoWfEQy27gi-IERRqsJ5lSY0OJhsWOUQzjavAfF0_XV4-Vtef9wc3d5cV-uWN3GktNG86FVTNLGNA2AMZQxVZmeail1LTVAbwz0apCccS76ijV0qWpumOip5AfF6W93Haa3BBi70aIG55SHKWHXsOxbLjI83sDUjzB062BHFT66v5NlcLIBCvOpTFBeW_x3glLOa5bd2a9b2ZfVbAN0OCrncpZ38zwzmZMdE0vBvwAKPIZ4</recordid><startdate>20011101</startdate><enddate>20011101</enddate><creator>Jacobsen, S</creator><creator>Ullman, S</creator><creator>Shen, G Q</creator><creator>Wiik, A</creator><creator>Halberg, P</creator><general>The Journal of Rheumatology</general><general>Journal of Rheumatology Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20011101</creationdate><title>Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis</title><author>Jacobsen, S ; Ullman, S ; Shen, G Q ; Wiik, A ; Halberg, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h269t-317c3d9a2817f77eeff122a0fb1c88c68ceebffebad832334b02715a63f24b183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Antinuclear - blood</topic><topic>Biological and medical sciences</topic><topic>Cause of Death</topic><topic>Child</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Heart Diseases - etiology</topic><topic>Heart Diseases - mortality</topic><topic>Heart Diseases - pathology</topic><topic>Humans</topic><topic>Kidney Diseases - etiology</topic><topic>Kidney Diseases - mortality</topic><topic>Kidney Diseases - pathology</topic><topic>Lung - pathology</topic><topic>Lung - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Pulmonary Fibrosis - etiology</topic><topic>Pulmonary Fibrosis - mortality</topic><topic>Pulmonary Fibrosis - pathology</topic><topic>Respiratory Function Tests</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Scleroderma, Systemic - complications</topic><topic>Scleroderma, Systemic - mortality</topic><topic>Scleroderma, Systemic - pathology</topic><topic>Survival Analysis</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jacobsen, S</creatorcontrib><creatorcontrib>Ullman, S</creatorcontrib><creatorcontrib>Shen, G Q</creatorcontrib><creatorcontrib>Wiik, A</creatorcontrib><creatorcontrib>Halberg, P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jacobsen, S</au><au>Ullman, S</au><au>Shen, G Q</au><au>Wiik, A</au><au>Halberg, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis</atitle><jtitle>Journal of rheumatology</jtitle><addtitle>J Rheumatol</addtitle><date>2001-11-01</date><risdate>2001</risdate><volume>28</volume><issue>11</issue><spage>2454</spage><epage>2459</epage><pages>2454-2459</pages><issn>0315-162X</issn><eissn>1499-2752</eissn><coden>JRHUA9</coden><abstract>OBJECTIVE: To evaluate the independent contribution of several clinical and laboratory variables to the mortality of a cohort
of Danish patients with systemic sclerosis (SSc). METHODS: A cohort of 174 patients with incident SSc was retrospectively
identified using clinical charts and study records of all new patients with SSc. Disease onset was defined as the time of
onset of cutaneous sclerosis. Vital status and causes of death were determined at the end of the observation period. Data
on clinical status and pulmonary function were obtained. Antitopoisomerase I (anti-topo I), anticentromere, anti-U1-RNP, anti-U3-RNP,
anti-Th-RNP, and anti-RNA polymerase (anti-RNAP) antibodies were determined by means of double immunodiffusion, immunofluorescence,
hemagglutination technique, radioactively labelled antisense riboprobes, and ELISA, respectively. RESULTS: Patients were followed
for a mean period of 13.3 yrs; 16 died of an SSc related condition and 50 of other causes. Pulmonary fibrosis, DLCO reduction
< 40% of the expected, diffuse cutaneous involvement, SSc nephropathy, cardiac disease, and anti-topo I and anti-RNAP antibody
were related to decreased survival due to SSc. Variables that entered a Cox regression model of SSc related mortality were
right heart failure (RR 12.4, 95% CI 2.5-60), diffuse SSc (RR 7.8, 95% CI 1.8-35), SSc nephropathy (RR 6.1, 95% CI 1.8-21),
and DLCO < 40% (RR 4.8, 95% CI 1.1-20). The relative risk of developing right heart failure and diffuse SSc given the presence
of anti-RNAP antibody was 14 (p = 0.0001) and 1.9 (p = 0.01), respectively. The corresponding figures for anti-topo I antibody
were 4.6 (p = 0.02) and 2.0 (p = 0.01). CONCLUSION: SSc related mortality was associated with right heart failure and diffuse
SSc, both of which were also associated with the presence of anti-topo I and anti-RNAP antibody. The prognostic value of these
autoantibodies may lie in the early course of the disease when specific morbidity has not yet evolved.</abstract><cop>Toronto, ON</cop><pub>The Journal of Rheumatology</pub><pmid>11708418</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0315-162X |
| ispartof | Journal of rheumatology, 2001-11, Vol.28 (11), p.2454-2459 |
| issn | 0315-162X 1499-2752 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72271934 |
| source | Medical Journals |
| subjects | Adolescent Adult Aged Aged, 80 and over Antibodies, Antinuclear - blood Biological and medical sciences Cause of Death Child Cohort Studies Female Heart Diseases - etiology Heart Diseases - mortality Heart Diseases - pathology Humans Kidney Diseases - etiology Kidney Diseases - mortality Kidney Diseases - pathology Lung - pathology Lung - physiopathology Male Medical sciences Middle Aged Prognosis Prospective Studies Pulmonary Fibrosis - etiology Pulmonary Fibrosis - mortality Pulmonary Fibrosis - pathology Respiratory Function Tests Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Scleroderma, Systemic - complications Scleroderma, Systemic - mortality Scleroderma, Systemic - pathology Survival Analysis Survival Rate |
| title | Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T12%3A44%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20clinical%20features,%20serum%20antinuclear%20antibodies,%20and%20lung%20function%20on%20survival%20of%20patients%20with%20systemic%20sclerosis&rft.jtitle=Journal%20of%20rheumatology&rft.au=Jacobsen,%20S&rft.date=2001-11-01&rft.volume=28&rft.issue=11&rft.spage=2454&rft.epage=2459&rft.pages=2454-2459&rft.issn=0315-162X&rft.eissn=1499-2752&rft.coden=JRHUA9&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E72271934%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h269t-317c3d9a2817f77eeff122a0fb1c88c68ceebffebad832334b02715a63f24b183%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72271934&rft_id=info:pmid/11708418&rfr_iscdi=true |